Valuation: H&R GmbH & Co KgaA

Market Cap 229M 262M 212M 196M 368M 25.2B 375M 2.53B 991M 12.32B 984M 962M 42.48B P/E 2026 *
39.2x
P/E 2027 * 28.9x
Enterprise Value 385M 440M 356M 329M 619M 42.35B 631M 4.25B 1.67B 20.71B 1.65B 1.62B 71.4B EV / Sales 2026 *
0.3x
EV / Sales 2027 * 0.29x
Free-Float
21.97%
Yield 2026 *
0.81%
Yield 2027 * 0.81%
05-15 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-28 Kepler Cheuvreux Favors BASF and Bayer, Avoids H&R and Evonik DP
11-15 H&R GmbH & Co. KGaA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-14 H&R GmbH & Co. KGaA Revises Earnings Guidance for the Full Year 2025 CI
25/08/25 Nils Hansen acquired additional 7.78% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?15 million. CI
15/08/25 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
16/05/25 Nils Hansen proposed to acquire remaining 38.55% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?73 million. CI
14/05/25 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
16/04/25 H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 CI
09/04/25 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2024 CI
26/03/25 H&R GmbH & Co. KGaA Says Postponement Of The Publication Of The Consolidated Financial Statements And The Annual Report 2024 RE
26/03/25 H&R GmbH & Co. KGaA Announces Postponement of the Publication of the Consolidated Financial Statements and the Annual Report 2024 CI
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2016
Investor Relations Contact - 01/01/2006
Director TitleAgeSince
Chairman 62 17/04/2012
Director/Board Member 71 01/05/2011
Director/Board Member 69 01/05/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 258M
+1.01%+0.19%+12.30%+34.28% 128B
+5.26%+26.13%+667.82%+194.94% 49.17B
-0.29%+1.06%-4.90%-40.78% 41.94B
+3.96%-2.00%+24.91%-24.06% 30.91B
+6.32%+4.26%+41.22%+64.53% 22.22B
+0.39%+7.23%-7.12%-35.66% 18.82B
+0.55%-1.66%+335.94%+578.48% 17.13B
+0.72%-1.36%+18.59%+398.91% 17.17B
+2.12%-12.64%+60.37%+196.54% 16.71B
Average +2.00%+3.20%+127.68%+151.91% 38B
Weighted average by Cap. +2.05%+4.03%+125.27%+94.51%

Financials

2026 *2027 *
Net sales 1.29B 1.48B 1.2B 1.1B 2.08B 142B 2.12B 14.28B 5.59B 69.49B 5.55B 5.42B 240B 1.33B 1.52B 1.23B 1.13B 2.14B 146B 2.18B 14.68B 5.75B 71.47B 5.71B 5.58B 246B
Net income 5.85M 6.68M 5.41M 4.99M 9.39M 643M 9.58M 64.57M 25.27M 314M 25.09M 24.53M 1.08B 8M 9.13M 7.39M 6.82M 12.84M 879M 13.09M 88.26M 34.54M 430M 34.3M 33.53M 1.48B
Net Debt 156M 178M 144M 133M 251M 17.16B 256M 1.72B 675M 8.39B 670M 655M 28.92B 158M 180M 146M 135M 253M 17.34B 258M 1.74B 682M 8.48B 677M 662M 29.24B
Logo H&R GmbH & Co KgaA
H&R GmbH & Co KGaA is a Germany-based manufacturing of chemical and pharmaceutical speciality products. The Company’s two business activities are chemicals and pharmaceutical raw materials and precision plastic parts. It operates through three segments: ChemPharm Refining, ChemPharm Sales and Plastics. The ChemPharm Refining segment, which produces oils, technical and medical white oils as well as paraffins and wax products; the ChemPharm Sales segment, which produces plasticizers and wax emulsions and the Plastics segment manufacturing precision plastic parts as well as assemblies and medical consumables.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-